Vimta Labs Limited (VIMTALABS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.180x

Based on the latest financial reports, Vimta Labs Limited (VIMTALABS) has a cash flow conversion efficiency ratio of 0.180x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs748.73 Million ≈ $8.10 Million USD) by net assets (Rs4.16 Billion ≈ $45.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Vimta Labs Limited - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Vimta Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Vimta Labs Limited for a breakdown of total debt and financial obligations.

Vimta Labs Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vimta Labs Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Taj GVK Hotels & Resorts Limited
NSE:TAJGVK
0.039x
Insecticides (India) Limited
NSE:INSECTICID
-0.101x
Cint Group AB
ST:CINT
0.102x
Exicon Co. Ltd
KQ:092870
-0.041x
Fynske Bank A/S
CO:FYNBK
0.001x
Bank Woori Saudara Indonesia 1906
JK:SDRA
-0.049x
Cathay Chemical Works Inc
TW:1713
0.062x
Korea Asset In Trust Co Ltd
KO:123890
0.171x

Annual Cash Flow Conversion Efficiency for Vimta Labs Limited (2006–2025)

The table below shows the annual cash flow conversion efficiency of Vimta Labs Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Vimta Labs Limited.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs3.79 Billion
≈ $40.97 Million
Rs948.30 Million
≈ $10.26 Million
0.250x +31.42%
2024-03-31 Rs3.20 Billion
≈ $34.57 Million
Rs608.92 Million
≈ $6.59 Million
0.190x -38.97%
2023-03-31 Rs2.82 Billion
≈ $30.47 Million
Rs879.37 Million
≈ $9.51 Million
0.312x +23.62%
2022-03-31 Rs2.34 Billion
≈ $25.30 Million
Rs590.69 Million
≈ $6.39 Million
0.252x +31.98%
2021-03-31 Rs1.94 Billion
≈ $21.02 Million
Rs371.82 Million
≈ $4.02 Million
0.191x +35.82%
2020-03-31 Rs1.73 Billion
≈ $18.70 Million
Rs243.48 Million
≈ $2.63 Million
0.141x -38.28%
2019-03-31 Rs1.72 Billion
≈ $18.55 Million
Rs391.46 Million
≈ $4.23 Million
0.228x +4.81%
2018-03-31 Rs1.52 Billion
≈ $16.44 Million
Rs331.05 Million
≈ $3.58 Million
0.218x +23.92%
2017-03-31 Rs1.36 Billion
≈ $14.72 Million
Rs239.20 Million
≈ $2.59 Million
0.176x +2276.78%
2016-03-31 Rs1.26 Billion
≈ $13.64 Million
Rs-10.18 Million
≈ $-110.07K
-0.008x -106.45%
2015-03-31 Rs1.22 Billion
≈ $13.23 Million
Rs153.06 Million
≈ $1.66 Million
0.125x -10.34%
2014-03-31 Rs1.20 Billion
≈ $13.02 Million
Rs168.00 Million
≈ $1.82 Million
0.140x +1.10%
2013-03-31 Rs1.12 Billion
≈ $12.15 Million
Rs155.03 Million
≈ $1.68 Million
0.138x +16.97%
2012-03-31 Rs1.10 Billion
≈ $11.86 Million
Rs129.39 Million
≈ $1.40 Million
0.118x +77.91%
2011-03-31 Rs1.25 Billion
≈ $13.52 Million
Rs82.93 Million
≈ $896.82K
0.066x -64.58%
2010-03-31 Rs1.31 Billion
≈ $14.14 Million
Rs244.77 Million
≈ $2.65 Million
0.187x +1.40%
2009-03-31 Rs1.30 Billion
≈ $14.07 Million
Rs240.30 Million
≈ $2.60 Million
0.185x +83.97%
2008-03-31 Rs1.28 Billion
≈ $13.86 Million
Rs128.64 Million
≈ $1.39 Million
0.100x +418.23%
2007-03-31 Rs1.24 Billion
≈ $13.41 Million
Rs24.01 Million
≈ $259.70K
0.019x -88.04%
2006-03-31 Rs1.17 Billion
≈ $12.69 Million
Rs189.93 Million
≈ $2.05 Million
0.162x --

About Vimta Labs Limited

NSE:VIMTALABS India Diagnostics & Research
Market Cap
$220.67 Million
Rs20.40 Billion INR
Market Cap Rank
#16155 Global
#808 in India
Share Price
Rs457.15
Change (1 day)
+1.46%
52-Week Range
Rs380.70 - Rs1071.90
All Time High
Rs1155.00
About

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract researc… Read more